B Cell Engineering Service for Anti-Sarcoma Antibody Delivery

With advanced technologies and rich experience, Creative Biolabs has been an excellent service provider in the field of engineering B cells for therapeutic delivery. After years of comprehensive research on tumor markers, we launch our B cell engineering service which can be used in targeted therapy research for sarcomas.

The Introduction of Sarcomas Therapeutics

Sarcomas is a malignant solid tumor with high heterogeneity, which includes a large number of unique subtypes, more than 60 types. In recent years, targeted therapy based on the molecular and genetic phenotype of individual sarcomas has been a promising option for the treatment of sarcomas, meanwhile, several drugs have been approved for use to treat sarcomas.

Approved drugs and the respective targets for sarcomas treatment. Fig.1 Approved drugs and the respective targets for sarcomas treatment. (Damerell, et al., 2021)

B Cell Engineering Service for Anti-Sarcoma Antibody Delivery

Although some of the oncogenic factors and pathways that drive the development of sarcoma genesis have been identified, and targeted therapies have been developed, the treatment effectiveness of sarcomas still faces a great challenge. Based on long years of experience in tumor immunity, Creative Biolabs developed a B cell engineering service platform to accelerate sarcoma antibody research. We are dedicated to providing B cell engineering services for anti-lymphoma antibody delivery. You can refer to the following flowchart for the one-stop B cell engineering service.

Flowchart of B Cell Engineering Service. Fig.2 Flowchart of B Cell Engineering Service. (Creative Biolabs)

B Cell Engineering Service for Several Sarcoma Subtypes

Based on the large array of sarcoma subtypes, a high degree of intrinsic heterogeneity, the variability in many signaling pathways, and unsatisfactory responses to treatment. We developed a B Cell engineering service for anti-sarcoma antibody delivery based on different sarcoma subtypes to speed up sarcoma antibody research.

chematic representation of the most frequently occurring soft tissue and bone sarcomas. (Damerell, et al., 2021) Fig.3 Schematic representation of the most frequently occurring soft tissue and bone sarcomas. (Damerell, et al., 2021)

B Cell Engineering Service for Anti-Sarcoma Antibody Delivery via Several Hot Targets

We launched a B cell engineering service for anti-sarcoma antibody delivery based on a lot of popular targets, by targeting different pathways. There are several exciting targets you can choose to design for, including but not limited to:

  • Targeting tumor antigen or TME:
    PD1; CTLA-4; GD2; GD3; CD47; B7H3; TIM3; Endoglin; CD133; gp72; CD146;
  • Targeting angiogenesis: VEGFR; KIT;
  • Targeting sustained proliferation signaling: MET; mTOR; IGFR1; PDGFR; GF2R; FZD10;

For more details about our B cell engineering service for anti-sarcoma antibody delivery, please don't hesitate to contact us for more information.

Reference
  1. Damerell, V.; et al. Molecular mechanisms underpinning sarcomas and implications for current and future therapy. Signal transduction and targeted therapy. 2021, 6(1): 246.

Related Sections: